Integrative Metabolomics and Gut Microbiome Profiling for Deciphering the Anti-Obesity Mechanisms of Natural Polysaccharides
Keywords:
integrative metabolomics, gut microbiome, natural polysaccharides, obesity, systems architecture, multi-omics integration, data governance, precision nutrition, artificial intelligence, health equityAbstract
Obesity constitutes a multifactorial metabolic pandemic driven by complex cross-scale interactions between host genetics, dietary patterns, gut microbial ecology, and socio-environmental infrastructure. Natural polysaccharides have emerged as promising anti-obesity agents, yet their mechanisms remain opaque due to the systemic, multi-target nature of their bioactivity. Contemporary research necessitates integrative metabolomics and gut microbiome profiling to dissect these mechanisms, but the transition from reductionist experiments to robust, translatable knowledge mandates a rigorous systems-level architecture. This paper examines the structural trade-offs, analytical infrastructures, computational governance, and policy frameworks required to construct a sustainable, equitable pipeline for deciphering anti-obesity polysaccharides. We critically evaluate the multi-omics data integration architecture, discussing the harmonization of mass spectrometry-based metabolomics with high-throughput metagenomic sequencing, the deployment of scalable bioinformatics platforms, and the application of artificial intelligence for network-level mechanism inference. Emphasis is placed on the resilience and reproducibility of analytical workflows, the fairness implications of population-representative microbiome reference panels, and the translational sustainability from experimental models to precision nutrition. Through the lens of systems engineering and socio-technical governance, we argue that unlocking the therapeutic potential of natural polysaccharides demands not only biochemical insight but a reconfiguration of collaborative research infrastructure, data standardization protocols, and ethical oversight mechanisms. The paper identifies gaps in current deployment strategies and proposes a forward-looking framework that aligns computational rigor, polycentric data stewardship, and health equity. In doing so, it provides a roadmap for bridging the molecular understanding of polysaccharide-microbiome-host axes with the real-world implementation of anti-obesity interventions.
References
1. Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 444(7122), 1027–1031.
2. Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006). Human gut microbes associated with obesity. Nature, 444(7122), 1022–1023.
3. Cani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., & Burcelin, R. (2008). Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes, 57(6), 1470–1481.
4. Holmes, E., Loo, R. L., Stamler, J., Bictash, M., Yap, I. K., Chan, Q., ... & Elliott, P. (2008). Human metabolic phenotype diversity and its association with diet and blood pressure. Nature, 453(7193), 396–400.
5. Nicholson, J. K., & Lindon, J. C. (2008). Systems biology: Metabonomics. Nature, 455(7216), 1054–1056.
6. Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., ... & Wang, J. (2012). A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature, 490(7418), 55–60.
7. Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., ... & Caporaso, J. G. (2019). Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nature Biotechnology, 37(8), 852–857.
8. Wishart, D. S., Feunang, Y. D., Marcu, A., Guo, A. C., Liang, K., Vázquez-Fresno, R., ... & Scalbert, A. (2018). HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Research, 46(D1), D608–D617.
9. Hasin, Y., Seldin, M., & Lusis, A. (2017). Multi-omics approaches to disease. Genome Biology, 18(1), 83.
10. Karczewski, K. J., & Snyder, M. P. (2018). Integrative omics for health and disease. Nature Reviews Genetics, 19(5), 299–310.
11. Barabási, A. L., Gulbahce, N., & Loscalzo, J. (2011). Network medicine: a network-based approach to human disease. Nature Reviews Genetics, 12(1), 56–68.
12. Xu, X., Li, W., Li, T., Li, Y., Zheng, X., & Li, J. (2015). A polysaccharide from the roots of Panax ginseng retards obesity in rats by regulating gut microbiota. Food & Function, 6(8), 2764–2771.
13. Chang, C. J., Lin, C. S., Lu, C. C., Martel, J., Ko, Y. F., Ojcius, D. M., ... & Young, J. D. (2015). Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nature Communications, 6, 7489.
14. den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D. J., & Bakker, B. M. (2013). The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. Journal of Lipid Research, 54(9), 2325–2340.
15. Schoeler, M., & Caesar, R. (2019). Dietary lipids, gut microbiota and lipid metabolism. Reviews in Endocrine and Metabolic Disorders, 20(4), 461–472.
16. Sumner, L. W., Amberg, A., Barrett, D., Beale, M. H., Beger, R., Daykin, C. A., ... & Viant, M. R. (2007). Proposed minimum reporting standards for chemical analysis. Metabolomics, 3(3), 211–221.
17. Zhao K, et al. Phyllostachys nigra (Lodd ex Lindl) derived polysaccharide with enhanced glycolipid metabolism regulation and mice gut microbiome. Int J Biol Macromol. 2024;257:128588.
18. Johnson, C. H., Ivanisevic, J., & Siuzdak, G. (2016). Metabolomics: beyond biomarkers and towards mechanisms. Nature Reviews Molecular Cell Biology, 17(7), 451–459.
19. Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., Appleton, G., Axton, M., Baak, A., ... & Mons, B. (2016). The FAIR Guiding Principles for scientific data management and stewardship. Scientific Data, 3, 160018.
20. Liebal, U. W., Phan, A. N. T., Sudhakar, M., Raman, K., & Blank, L. M. (2020). Machine learning applications in microbiology. FEMS Microbiology Reviews, 44(2), 230–246.
21. Sen, P., Lamichhane, S., Mathema, V. B., McGlinchey, A., Orešič, M., & Hyötyläinen, T. (2020). Deep learning meets metabolomics: a methodological perspective. Briefings in Bioinformatics, 21(4), 1318–1328.
22. Kumanyika, S. K. (2019). A framework for increasing equity impact in obesity prevention. American Journal of Public Health, 109(10), 1350–1357.
23. Zmora, N., Zilberman-Schapira, G., Suez, J., Mor, U., Dori-Bachash, M., Bashiardes, S., ... & Elinav, E. (2018). Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell, 174(6), 1388–1405.e21.
24. Li, W., Zhang, S., & Smith, C. (2020). Natural polysaccharides for the treatment of metabolic disorders: A review of structures and microbiota-mediated mechanisms. Pharmacological Research, 158, 104924.
25. Wang, M., Liu, Y., Xue, B., & Gao, X. (2021). Natural polysaccharides targeting gut microbiota for treatment of metabolic diseases: An overview. Carbohydrate Polymers, 272, 118517.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 International Journal of Clinical and Translational Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
This article is published under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
